Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025